The FDA’s Office of Combination Products (OCP) has issued revised guidance intended to help medical product sponsors obtain a preliminary assessment from the agency of the regulatory identity or classification of a product as a drug, a device, a biological product, or a combination product. The guidance also outlines the process through which a product sponsor can obtain info... Read More